Wolberg, Alisa S.
Rosendaal, Frits R.
Weitz, Jeffrey I.
Jaffer, Iqbal H.
Agnelli, Giancarlo
Baglin, Trevor
Mackman, Nigel
Article History
First Online: 7 May 2015
Competing interests
: G.A. has received personal fees from Boehringer Ingelheim, Bayer Healthcare, Daiichi Sankyo, Sanofi, Pfizer and Bristol–Myers Squibb; all are outside the scope of the submitted work. T.B. has received honoraria for participating in scientific advisory boards for Boehringer Ingelheim and Daiichi Sankyo, and has received an unconditional travel grant from Boehringer Ingelheim. N.M. served as consultant to Merck and Bayer. F.R.R. is listed on several patents for prothrombotic gene variants. J.I.W. served as a consultant to and received honoraria from Boehringer Ingelheim, Bristol–Myers Squibb, Pfizer, Johnson & Johnson, Daiichi Sankyo, ISIS Pharmaceuticals and Portola. A.S.W. served as a consultant to Merck. I.H.J. has no competing financial interests to report.